Home
overview
As the number of cases of diabetes continues to grow rapidly, there is an increasing demand for more efficacious treatments and quick, cost-effective diagnostic tools. At SMi’s latest international pharmaceuticals conference Diabetes 2001, we have researched this area so that in just two days you can gain all the latest information and developments on diabetes.

This meeting aims to bring together experts from within the field of diabetes, to offer an insight into the novel diagnostic methods and therapies now available and future developments.

Why should you attend this event? This comprehensive conference is organised and produced by SMi: we have identified diabetes as a targeted sector for executives anxious to keep a close eye on industry developments. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions. The conference will of course also be an ideal opportunity for you to network with a focused and appropriate audience.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Professor Simon Howell

Professor Simon Howell, Head, School of Biomedical Sciences, King’s College London

9:10 BETTER DIABETES CARE

Dr Meng Tan

Dr Meng Tan, Medical Director, Global Diabetes Care, Eli Lilly

  • Diabetes- a common, growing, serious and costly health problem
  • Challenges of diabetes- impaired metabolism and complications of disease
  • Opportunities for better diabetes care- improve metabolic control and decrease complications
  • Rising to the challenge for more advanced and effective treatment therapies
  • 9:40 INTEGRATION OF GENOMICS AND BIOLOGY FOR NEW TARGET DISCOVERY IN TYPE 2 DIABETES

    Dr Thomas Gustafson

    Dr Thomas Gustafson, Vice President, Biology, Metabolex

  • Comprehensive gene profiling as a tool to understand the causes of diabetes and identify new drug targets
  • Design of custom Affymetrix GeneChip® arrays using a complete catalog of expressed genes in relevant human tissue
  • Human tissue samples – A critical component
  • Identification of differently expressed genes in affected tissues in the diabetic and obese patient
  • From GeneChip® to drug targets – Target identification and validation
  • 10:20 IDENTIFICATION AND VALIDATION OF DIABETES DRUG TARGETS

    Dr Alan Schafer

    Dr Alan Schafer, Vice President, Genetics, Incyte Genomics

  • Target identification using genomic technologies
  • Bioinformatics and target identification
  • Functional genomic approaches to target validation
  • Genetics and target validation
  • 11:00 Morning Coffee

    11:20 RISK STRATIFICATION AND TARGETING OF THERAPEUTIC INTERVENTIONS IN DIABETES

    Dr Kip Martha

    Dr Kip Martha, Chief Medical Officer, Vice President, Clinical Research and Development, Interleukin Genetics

  • What are disease modifying genes
  • How might disease modifying genes affect the risk of diabetic complications
  • Using knowledge of genetic variation for targeting new or costly diabetes interventions
  • Application of variation in disease modifying genes to diabetes drug development
  • 12:00 THE QUEST FOR TYPE 2 DIABETES GENES

    Dr Jan Pullen

    Dr Jan Pullen, Programme Manager, Oxagen

  • Oxagen’s Type 2 diabetes programme
  • The use of isolated, founder populations for the identification of genetic loci involved in Type 2 diabetes
  • Association and candidate gene studies
  • Using an integrated approach for gene discovery
  • 12:40 Lunch

    13:40 GENOMIC PROGRESS IN DIABETES

    Dr Narayanan Hariharan

    Dr Narayanan Hariharan, Principal Investigator, Department of Metabolic Research, Bristol-Myers Squibb

  • The importance of glucokinase in glycemic control
  • The use of glucokinase transgenic mice
  • Improving glycemic control through enhancing glucokinase activity
  • How the disruption of the regulatory protein leads to reduced glucokinase activity in the liver and impaired glycemic control
  • 14:20 NEW USES FOR ACARBOSE

    Dr James Magner

    Dr James Magner, Director, Global Clinical Strategy, Metabolics, Bayer

  • The clinical relevance of Impaired Fasting Glucose and Impaired Glucose Tolerance
  • Insights from the DECODE study
  • Insights from the recent Bayer study
  • Insights from the Diabetes Prevention Programme
  • Challenges for the future
  • 15:00 ARE STEM CELLS THE ANSWER TO ISLET SUPPLY PROBLEMS?

    Dr Alan Colman

    Dr Alan Colman, Research Director, PPL Therapeutics

  • Pancreatic development
  • Stem cell candidates-which offer the best hope? · Adult ductal cells · Other adult cells · Embryonic stem cells
  • How to avoid rejection · Immunosuppressive drugs · Tolerance strategies · Therapeutic cloning
  • Differentiation, storage and distribution of insulin producing cells
  • Validation and regulatory issues affecting cellular therapeutics
  • Future predictions
  • 15:40 Afternoon Tea

    16:00 REGENERATIVE MEDICINE FOR THE TREATMENT OF DIABETES

    Dr Thomas Knittel/Dr Luc St-Onge

    Dr Thomas Knittel/Dr Luc St-Onge, Vice President, Medical Affairs/Director, Diabetes Research, DeveloGen

  • Regenerative medicine as a novel therapy to treat diabetes and other diseases
  • Control pathways specifying beta cell development
  • Identification and validation of control genes important for beta cell development using functional genomics
  • Analysis of the potential progenitor cell populations essential for beta cell regeneration
  • Use of master control genes to regenerate beta cells – results from ex vivo and in vivo approaches
  • Future trends
  • 16:30 NOVEL THERAPEUTIC APPROACHES FOR TYPE 2 DIABETES

    Dr James McCormack

    Dr James McCormack, Vice President, Target Cell Biology, Novo Nordisk

  • NN622 – a dual activating PPAR a/g ligand and NN2211 – a long-acting GLP-1 analogue
  • NN622 – Dual acting agonist for both PPARa and PPARg
  • Improves insulin sensitivity and blood glucose
  • Together with favourable effects on lipid levels
  • NN2211 – harnessing the potential of GLP-1
  • GLP-1 a unique hormone with a 5-way mechanism of action

    Treating diabetes and obesity

  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Richard Palmer

    Dr Richard Palmer, Chief Executive Officer, Alizyme

    9:10 NOVEL DRUG DISCOVERY APPROACHES FOR METABOLIC DIEASES

    Dr Brett Monia

    Dr Brett Monia, Vice President, Antisense Drug Discovery, Isis Pharmaceuticals

  • Advantages over traditional drug discovery approaches
  • Antisense as a tool for target validation
  • Antisense oligonucleotides as drugs for the clinic
  • Phosphatase targeting
  • Novel target identification
  • Future challenges
  • 9:40 INSULIN WITHOUT INJECTION: THE GOAL OF DRUG DELIVERY

    Martin Cleary/Dr Roland Scollay

    Martin Cleary/Dr Roland Scollay, President & Chief Executive Officer / Vice President of Research & Chief Scientific Officer, Genetric

  • Eliminating the injection
  • The benefits of orally delivering the insulin gene
  • Easing control of the disease
  • How are the problems of common gene therapy overcome?
  • The challenges faced in the development of this treatment
  • The future outlook
  • 10:20 RECOMBINANT PRODUCTION AND ORAL DELIVERY OF GLUCOSE REGULATORY PEPTIDES

    Dr James Gilligan

    Dr James Gilligan, Vice President, Unigene Laboratories

  • Oral insulin
  • cGMP recombinant production of peptides
  • Development of oral peptide delivery formulations
  • 11:00 Morning Coffee

    11:20 NON INVASIVE TESTING WITH DIABETES

    Dr Stephen Monfre

    Dr Stephen Monfre, Vice President, Research & Development, Instrumentation Metrics

  • Non-invasive glucose sensors
  • Meeting daily needs
  • Clinical efficacy of non-invasive glucose sensors
  • Upgrading from spot to continuous glucose testing
  • The outlook for the future
  • 12:00 CLINICAL PHARMACOLOGY OF BASAL BOLUS INSULIN REGIMENS

    Dr Reinhard Becker

    Dr Reinhard Becker, Clinical Pharmacologist, Aventis Pharma Deutschland

  • Complementary long- and short-acting human insulin analogues
  • Time action / concentration profiling by euglycaemic clamps
  • Pre/post-meal administation
  • Alternative routes for delivery of regular human insulin
  • 12:40 Lunch

    14:00 COMBINATION THERAPY IN OBESITY

    Dr Gianni Gromo/Dr Jacques Mizrahi

    Dr Gianni Gromo/Dr Jacques Mizrahi, Global Head, Vascular & Metabolic Diseases / Head, Metabolic Diseases, F. Hoffmann-La Roche

  • Current therapies in Obesity: Appetite suppression, Satiety enhancers and Energy expenditure
  • Complimentarity and redundancy of central and peripheral pathways
  • Compensatory mechanisms
  • Combination or sequential therapy
  • 14:40 ANTI-OBESITY DRUGS AND DIABETES

    Dr Nick Livingston

    Dr Nick Livingston, Director, Diabetes Research, Bayer

  • The connection between obesity and diabetes
  • The need for pharmacological anti obesity agents
  • New targets for obesity and diabetes therapies
  • New therapies for obesity and diabetes
  • Challenges for the future
  • 15:20 Afternoon Tea

    15:40 DIABETIC COMPLICATIONS: FIGHTING BACK

    Dr László Tálosi

    Dr László Tálosi, R&D Director, Biorex Research and Development Company

  • Development of diabetic complications
  • Oxidative stress and the role of heat shock proteins
  • Co-induction of heat shock proteins as a therapeutic approach
  • Pre-clinical studies using BRX-345, a new heat shock protein co-inducer
  • Clinical data from Phase II studies of Bimoclomol
  • 16:20 DIABETES PREVENTION

    Dr Richard Pratley

    Dr Richard Pratley, Director, Diabetes & Obesity Section, Clinical Research & Development, Novartis Pharmaceuticals

  • The Navigator trial
  • Oral antidiabetic agent: Starlix
  • Implications of the trial
  • Where do we go now?
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.